125 related articles for article (PubMed ID: 37634476)
1. MiRNA-mRNA integrative analysis reveals epigenetically regulated and prognostic miR-103a with a role in migration and invasion of carboplatin-resistant ovarian cancer cells that acquired mesenchymal-like phenotype.
Pernar Kovač M; Tadić V; Kralj J; Milković Periša M; Orešković S; Babić I; Banović V; Zhang W; Culig Z; Brozovic A
Biomed Pharmacother; 2023 Oct; 166():115349. PubMed ID: 37634476
[TBL] [Abstract][Full Text] [Related]
2. Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.
Hassan MK; Waly AA; Elsayed W; Keshk S; Allam WR; El-Khamisy SF
Sci Rep; 2021 Jan; 11(1):562. PubMed ID: 33436648
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT.
Kralj J; Pernar Kovač M; Dabelić S; Polančec DS; Wachtmeister T; Köhrer K; Brozovic A
Br J Cancer; 2023 Mar; 128(7):1344-1359. PubMed ID: 36717670
[TBL] [Abstract][Full Text] [Related]
4. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
Brozovic A; Duran GE; Wang YC; Francisco EB; Sikic BI
Mol Oncol; 2015 Oct; 9(8):1678-93. PubMed ID: 26025631
[TBL] [Abstract][Full Text] [Related]
5. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
6. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
Zhang P; He M; Zeng Y; Cai X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA EPB41L4A-AS2 suppresses progression of ovarian cancer by sequestering microRNA-103a to upregulate transcription factor RUNX1T1.
Sun T; Yang P; Gao Y
Exp Physiol; 2020 Jan; 105(1):75-87. PubMed ID: 31645082
[TBL] [Abstract][Full Text] [Related]
9. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
Li Y; Li L
J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
[TBL] [Abstract][Full Text] [Related]
11. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
12. High-throughput sequencing identification of differentially expressed microRNAs in metastatic ovarian cancer with experimental validations.
Gu Y; Zhang S
Cancer Cell Int; 2020; 20():517. PubMed ID: 33100909
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
Xue B; Li S; Jin X; Liu L
BMC Cancer; 2021 Apr; 21(1):452. PubMed ID: 33892654
[TBL] [Abstract][Full Text] [Related]
14. miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance.
Wang X; Jiang L; Liu Q
J Transl Med; 2022 Jun; 20(1):258. PubMed ID: 35672774
[TBL] [Abstract][Full Text] [Related]
15. Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer.
Liu L; Zou J; Wang Q; Yin FQ; Zhang W; Li L
Tumour Biol; 2014 Aug; 35(8):7713-7. PubMed ID: 24805828
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer.
Pernar Kovač M; Tadić V; Kralj J; Duran GE; Stefanelli A; Stupin Polančec D; Dabelić S; Bačić N; Tomicic MT; Heffeter P; Sikic BI; Brozovic A
Cell Mol Life Sci; 2023 Sep; 80(10):294. PubMed ID: 37718345
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
18. miR-29c-3p regulates proliferation and migration in ovarian cancer by targeting KIF4A.
Feng S; Luo S; Ji C; Shi J
World J Surg Oncol; 2020 Dec; 18(1):315. PubMed ID: 33261630
[TBL] [Abstract][Full Text] [Related]
19. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
20. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
Zuo L; Li X; Tan Y; Zhu H; Xiao M
J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
